Kristen Ambrose sold $108k of VRTX
SVP & Chief Accounting Officer at VERTEX PHARMACEUTICALS INC / MA. 223 shares at an average of $486.35, traded Feb 25, 2026, filed Feb 26, 2026.
Score components
- +15RoleOfficer
- +10Trade size$108k at market
- 0Share of holdings soldSold 3.1% of holdings
- +15Cluster6 insiders selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000875320-26-000104, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Feb 24, 2026 | FTax withholding Common Stock10b5-1 | -546 | $485.11 | $265k | 7,204 | Feb 26, 2026 |
| Feb 25, 2026 | SOpen-market sale Common Stock10b5-1 | -223 | $486.35 | $108k | 6,981 | Feb 26, 2026 |
Related signals
Other insiders at VERTEX PHARMACEUTICALS INC / MA and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 20Weak | VERTEX PHARMACEUTICALS INC / MA | Carmen Bozic EVP and CMO | $1.1M 2,329 shares | -7% | |
| 20Weak | VERTEX PHARMACEUTICALS INC / MA | Carmen Bozic EVP and CMO | $1.1M 2,329 shares | -6% | |
| 35Weak | VERTEX PHARMACEUTICALS INC / MA | Carmen Bozic EVP and CMO | $1.1M 2,329 shares | -6% | |
| 21Weak | VERTEX PHARMACEUTICALS INC / MA | Kristen Ambrose SVP & Chief Accounting Officer | $173k 357 shares | -5% | |
| 24Weak | VERTEX PHARMACEUTICALS INC / MA | Edward Morrow Atkinson III EVP, Chief Technical Ops. Off. | $325k 668 shares | -3% | |
| 27Weak | VERTEX PHARMACEUTICALS INC / MA | Jonathan Biller EVP and Chief Legal Officer | $460k 945 shares | -6% | |
| 24Weak | VERTEX PHARMACEUTICALS INC / MA | Mark E. Bunnage EVP, Chief Scientific Officer | $302k 620 shares | -8% | |
| 40Moderate | VERTEX PHARMACEUTICALS INC / MA | Kristen Ambrose SVP & Chief Accounting Officer | $1.1M 2,195 shares | -22% | |
| 40Moderate | VERTEX PHARMACEUTICALS INC / MA | Edward Morrow Atkinson III EVP, Chief Technical Ops. Off. | $1.4M 2,848 shares | -12% | |
| 40Moderate | VERTEX PHARMACEUTICALS INC / MA | Jonathan Biller EVP and Chief Legal Officer | $1.8M 3,720 shares | -19% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.